A 股代码：688981 A 股简称：中芯国际 公告编号：2025-017 港股代码：00981 港股简称：中芯国际 中芯国际集成电路制造有限公司 首次授予部分第四个归属期及 预留授予部分第三个归属期符合归属条件的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 限制性股票拟归属数量：1,120.82 万股（首次授予部分 983.59 万股、预 留授予部分 137.23 万股） ? 归属股票来源：公司向激励对象定向发行公司 A 股普通股股票。 一、本次股权激励计划批准及实施情况 （一）本次股权激励计划方案及履行的程序 （1）股权激励方式：第二类限制性股票。 （2）授予数量：授予的限制性股票总量为 7,565.04 万股，约占公司 2021 年 科创板限制性股票激励计划（以下简称"激励计划"）草案公告时公司股本总额 告时公司股本总额的 0.85%；预留 811.52 万股，约占激励计划草案公告时公司股 本总额的 0.10%。 （3）授予价格：20 元/股，即满足授予条件和归属条件后，激励对象可以每 股 ...

Group 1 - Haitong Development reported a net profit of 86.87 million yuan for the first half of 2025, a year-on-year decrease of 64.14% [1] - Haitong Development achieved an operating income of 1.8 billion yuan, a year-on-year increase of 6.74% [1] - Crystal Integrated expects a net profit increase of 39.04% to 108.55% for the first half of 2025, with projected revenue between 5.07 billion yuan and 5.32 billion yuan [1] Group 2 - Aerospace Universe anticipates a net profit increase of 50.59% for the first half of 2025, with a projected net profit of 34.38 million yuan [2] - Aerospace Universe's net profit excluding non-recurring gains is expected to grow by 94.90% [2] Group 3 - Guodian Power reported a total power generation of 206.03 billion kWh for the first half of 2025, a year-on-year decrease of 3.61% [3] - The company's market-based transaction electricity accounted for 91.84% of the total electricity sold [3] Group 4 - Shanghai Pharmaceuticals announced that its tranexamic acid injection has passed the consistency evaluation for generic drugs [5] - The drug is primarily used for treating various bleeding disorders [5] Group 5 - Sanyou Chemical received approval to issue up to 900 million yuan in technology innovation corporate bonds [7] - The bond issuance is valid for 24 months from the date of approval [7] Group 6 - Baiyuntian's BAT4406F injection drug has received approval for clinical trials for additional indications [9] - The drug is a next-generation fully human anti-CD20 antibody [9] Group 7 - Huason Pharmaceutical received three drug re-registration approval notices [10] - The approved drugs include Ganji Bingmei tablets and other formulations [10] Group 8 - Shanying International plans to establish the Zhiyuan Fund with a total scale of 100 million yuan [13] - The fund will primarily invest in product companies related to industrial scenarios [13] Group 9 - Yiqiu Resources announced the sale of two properties in Malaysia for a total of approximately 3.67 million yuan [15] - The sale is part of the company's asset management strategy [15] Group 10 - Guizhou Bailing plans to apply for loans totaling no more than 920 million yuan from multiple banks [16] - The loans will be used to replace maturing loans and supplement working capital [16] Group 11 - Samsung Medical's subsidiary won a transformer procurement contract in Brazil worth approximately 341 million yuan [16] - The contract is part of the company's expansion into international markets [16] Group 12 - Changying Tong expects a net profit increase of 72.12% to 110.33% for the first half of 2025 [17] - The projected revenue is between 173 million yuan and 211 million yuan [17] Group 13 - Canqin Technology anticipates a net profit increase of 50.14% to 61.85% for the first half of 2025 [17] - The expected revenue is between 286 million yuan and 290 million yuan [17] Group 14 - Daya Shengxiang signed a lease agreement with an annual rent of 17 million yuan for a production facility [18] - The lease term is for 3 years and 4 months, including a 4-month rent-free period [18] Group 15 - Zhongzai Zihuan announced the resignation of its general manager due to work adjustments [20] - The company will appoint an interim general manager while searching for a permanent replacement [20] Group 16 - Fuwei Co. received a project notification from a well-known luxury brand for seat development [22] - The total sales amount for the project is expected to reach 4.9 billion yuan [22] Group 17 - Meili Technology's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [26] - The issuance is subject to further approval from regulatory authorities [26] Group 18 - Jinzhik Technology announced a stock suspension due to potential control changes [27] - The suspension is expected to last no more than two trading days [27] Group 19 - Zhongtian Technology plans to distribute a cash dividend of 3 yuan per 10 shares [28] - The dividend distribution date is set for July 25, 2025 [28] Group 20 - Huahai Chengke plans to distribute a cash dividend of 0.2002 yuan per share [30] - The dividend distribution date is set for July 29, 2025 [30] Group 21 - Dasheng Intelligent won a smart transportation project contract worth 122 million yuan [31] - The project involves comprehensive monitoring systems for urban rail transit [31] Group 22 - Dongyue Silicon reported a fire incident affecting production operations [32] - The fire has been controlled, but the extent of damage is still being assessed [32] Group 23 - Shaanxi Guotou A reported a net profit of 726 million yuan for the first half of 2025, a year-on-year increase of 5.74% [35] - The company's operating income decreased by 2.95% [35] Group 24 - Yibo Technology announced a plan to reduce shareholding by up to 3% [37] - The reduction is due to the shareholder's funding needs [37] Group 25 - Xiling Information announced a stock suspension due to potential control changes [39] - The suspension is expected to last no more than two trading days [39] Group 26 - Tianli Lithium Energy plans to reduce shareholding by 4.55% through block trading [40] - The reduction is due to the fund's operational timeline nearing its end [40] Group 27 - Sihui Fushi announced plans for a combined shareholding reduction of up to 3% [42] - The reduction is due to the shareholders' personal funding needs [42] Group 28 - Jinma Leisure announced a plan for a combined shareholding reduction of up to 4.83% [44] - The reduction is due to personal funding needs of the controlling shareholder and executives [44] Group 29 - *ST Zitian's stock may be terminated due to financial reporting issues [46] - The company is under regulatory scrutiny for failing to rectify its financial statements [46]

Core Viewpoint - The company expects a significant increase in net profit for the first half of 2025, projecting a year-on-year growth of 39.04% to 108.55% [1] Financial Performance - The estimated net profit attributable to the parent company is projected to be between 260 million and 390 million yuan [1] - The growth in performance is primarily driven by the recovery in industry conditions, increased product sales, and high capacity utilization [1] Product and Market Dynamics - The increase in revenue and gross profit is attributed to the rise in sales volume and the higher proportion of CIS products [1]

Core Insights - July 18 marked a significant day for the capital market with multiple key approvals from the China Securities Regulatory Commission (CSRC) [1] - The approvals indicate an acceleration in the review process for quality mergers and acquisitions, as well as a more inclusive approach for IPOs on the Sci-Tech Innovation Board [1][7] Group 1: Mergers and Acquisitions - The CSRC approved China Shipbuilding Industry Company’s absorption merger with China Shipbuilding Heavy Industry Company, marking a significant step in the integration of two major listed platforms under the China Shipbuilding Group [2] - The merger is the first to complete the Shanghai Stock Exchange review and CSRC registration under the new restructuring regulations, setting a precedent for future mergers [2] - ChipLink Integrated Circuit Manufacturing Co. received approval for a significant asset restructuring deal, involving the acquisition of 72.33% of ChipLink Yuezhou Integrated Circuit Manufacturing for a total transaction value of 5.897 billion yuan, despite both companies currently being unprofitable [2][3] Group 2: Initial Public Offerings (IPOs) - Wuhan Heyuan Biotechnology Co. became the first company to receive IPO registration approval under the newly restarted fifth set of standards on the Sci-Tech Innovation Board [4] - Heyuan Biotechnology plans to raise 2.4 billion yuan for the construction of a recombinant human albumin production base, new drug development, and to supplement working capital [5] - Shenzhen Beixin Life Technology Co. also passed the listing review under the new standards, focusing on high-performance innovative medical devices for cardiovascular interventions [5] - Yushu Technology has initiated the IPO counseling process, with plans for a comprehensive evaluation of its listing conditions by October 2025 [5][6]

Group 1 - The core viewpoint is that TSMC (TSM.N) expects its revenue for the third quarter to be between $31.8 billion and $33 billion [1]

Core Insights - TSMC's net profit for the second quarter increased by 61% year-on-year [1] Financial Performance - The company reported a significant rise in net profit, indicating strong financial health and operational efficiency [1]

Group 1 - TSMC reported a gross margin of 58.6% for the second quarter, exceeding market expectations of 57.9% [1]

Economic Overview - In the first half of 2025, Sichuan's economy showed stable growth in production demand, with overall economic operation remaining steady and improving [4] - The average urban unemployment rate was 5.3%, unchanged from the same period last year [4] Income and Consumption - The per capita disposable income reached 18,779 yuan, a nominal increase of 5.6%, with a real growth of 5.8% after adjusting for price factors [4] - Per capita consumption expenditure was 12,208 yuan, with a nominal growth of 6.2%, outpacing the growth of disposable income by 0.6% [11] - The growth in consumption was driven by policies promoting the replacement of old consumer goods and strong holiday economic activities [11] Agricultural Production - The summer grain planting area was 17.032 million mu, an increase of 0.6% year-on-year, with a yield of 279.6 kg/mu, up by 1.8% [4] - Total grain production reached 4.762 million tons, a year-on-year increase of 2.4% [4] Livestock and Meat Production - The number of pigs slaughtered was 30.804 million, a year-on-year increase of 1.0%, with pork production at 2.438 million tons, up by 3.1% [6] - Pork prices have been declining, attributed to increased supply and seasonal demand fluctuations [6] Price Trends - The Consumer Price Index (CPI) in Sichuan decreased by 0.2% year-on-year, consistent with national trends [7] - The core CPI, excluding food and energy prices, increased by 0.3%, indicating a better performance than the overall CPI [9] - Service prices rose by 0.3% due to increased consumer spending in services, while food prices fell by 0.7% [8] Industrial Price Index - The Producer Price Index (PPI) decreased by 2.8% year-on-year, with a more significant decline compared to the previous year [9] - However, some sectors, particularly high-tech industries, showed price increases, with electronic components rising by 2.7% and integrated circuits by 4.4% [10]

Group 1 - The company held its 10th meeting of the second Supervisory Board on July 14, 2025, in Hefei, Anhui Province, with all procedures complying with relevant laws and regulations [1] - The Supervisory Board approved the adjustment of the grant price for the 2023 restricted stock incentive plan, stating that it aligns with legal regulations and does not harm the interests of the company and shareholders [1][2] - The Supervisory Board also approved the adjustment of the purchase price for the 2025 employee stock ownership plan, confirming compliance with relevant laws and regulations [2] - The decision to cancel 35,000 unvested restricted stocks from the 2023 incentive plan was approved, with the board affirming that it does not harm the interests of the company and shareholders [3] - The board agreed that the conditions for the second vesting period of the 2023 restricted stock incentive plan had been met, allowing for the vesting of stocks for eligible participants [4]

Core Viewpoint - The legal opinion letter confirms that Hefei Xinhui Microelectronics Co., Ltd. has complied with necessary approvals and authorizations regarding the adjustment of stock grant prices, the first grant of the second vesting period, and the cancellation of certain restricted stocks under the 2023 Restricted Stock Incentive Plan [4][15]. Summary by Sections Approval and Authorization - On May 29, 2023, the company's board approved the draft of the 2023 Restricted Stock Incentive Plan and related proposals, with independent directors providing their opinions [4][5]. - The supervisory board also approved the relevant proposals and confirmed the eligibility of the incentive objects on the same date [5]. - The first extraordinary general meeting of shareholders on June 15, 2023, approved the draft of the incentive plan and authorized the board to handle related matters [6]. - Subsequent meetings in June 2024 and July 2025 further approved adjustments to the grant price and the vesting conditions [6][7]. Adjustment Details - The adjustment of the grant price was necessitated by the company's 2024 annual equity distribution plan, which involved a cash dividend of approximately 0.0936 yuan per share [8]. - The adjusted grant price for the restricted stocks is approximately 6.49 yuan per share, calculated based on the formula provided in the incentive plan [8]. Vesting Conditions - The second vesting period for the first grant of restricted stocks is set from June 17, 2025, to June 16, 2026, while the first vesting period for reserved stocks is from June 14, 2025, to June 13, 2026 [9][10]. - The vesting conditions have been met, as the company has not encountered any disqualifying events as outlined in the incentive plan [10][11]. Performance Metrics - The performance assessment for the second vesting period is based on the company's revenue growth, with a target growth rate of 60% for full vesting [12]. - The company reported a revenue of approximately 1.5 billion yuan for 2024, reflecting a growth rate of 91.27% compared to the average revenue from 2020 to 2022 [12]. - For the first vesting period, the company reported a revenue of approximately 1.24 billion yuan for 2023, with a growth rate of 57.79% [13]. Cancellation of Restricted Stocks - The company has canceled 35,000 shares of restricted stocks due to one incentive object leaving the company, which disqualifies them from the incentive plan [14][15]. - The cancellation aligns with the provisions of the incentive plan regarding the treatment of unvested stocks for departing employees [15].